Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]
Eisai Submits Marketing Autherization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
Eisai and Biogen have announced that Eisai has submitted a marketing authorization application (MAA) for […]
Ionis and Royalty Pharma Enter Into Royalty Agreement for Up to $1.1 billion
Ionis Pharmaceuticals and Royalty Pharma plc today announced that Royalty Pharma has acquired an interest […]
Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis
Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout […]
FDA Approval of Aducanumab
Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s […]
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more